By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site.
Industry: Drug Manufacturers - General
Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
Institution %: 81.719
YTD Institution change: -6166419
InsidersInsiders %: 0.177
Insiders Purchases YTD: 2720
Insiders Sales YTD:
Insiders Net YTD: 2720
Analyst RatingsTarget Price: 29.29
Overall Rating: 3.3333
Strong Buys (5): 1
Buys (4): 3
Holds (3): 3
Sells (2): 2
Strong Sells (1): 0
52 Week Hi: 22.6968
52 Week Low: 10.6459
Beta: 0.796
50 Day MA: 16.8588
200 Day MA: 19.1745
Earnings / Revenue TrendsQtr Earnings Growth YOY: 5.081
Qtr Revenue Growth YOY: 0.041
Forward PE:
Trailing PE: